Skip to main content
. Author manuscript; available in PMC: 2016 Apr 11.
Published in final edited form as: J Posit Psychol. 2015;10(6):477–488. doi: 10.1080/17439760.2015.1015158

Table 1.

Sample Characteristics

Total Sample Three Good Things Placebo
Variable Possible
Range
Sample
Range
Mean (Standard
Deviation) or
Percentage
N Mean
(Standard
Deviation) or
Percentage
n Mean
(Standard
Deviation) or
Percentage
n
Demographic Characteristics at Baseline
Age 27–63 46.3 (10.9) 23 44.5 (10.9) 11 47.9 (11.1) 12
Years of Education 12–22 16.2 (3.0) 23 16.3 (3.9) 11 16.1 (2.0) 12
Female 11 (47.8%) 23 4 (36.4%) 11 7 (58.3%) 12
Not European-American 2 (8.7%) 23 2 (18.2%) 11 0 (0%) 12
Married or Co-habitating 11 (47.8%) 23 4 (36.4%) 11 7 (58.3%) 12
Employed Full-Time 13 (56.5%) 23 8 (72.7%) 11 5 (41.7%) 12
Clinical Characteristics at Baseline
Depression** 0–21 0–13 5.0 (3.9) 23 4.9 (3.9) 11 5.0 (4.1) 12
Anxiety** 0–21 3–18 9.1 (3.7) 23 9.5 (1.6) 11 8.8 (4.9) 12
Craving*** 0–56 0–29 10.3 (7.4) 23 10.3 (7.1) 11 10.3 (7.9) 12
Consequences of Drinking**** 0–45 0–37 8.3 (11.2) 23 4.9 (9.7) 11 11.5 (12.0) 12
AA Involvement***** 0–9 0–8.8 6.3 (2.6) 23 6.6 (2.6) 11 6.0 (2.7) 12
Days Since Last Substance Use 15–1855 430.6 (520.4) 23 339.5 (343.2) 11 514.2 (647.0) 12
Affect
Day 1
  Negative Affect (NA) 10–50 10–32 15.0 (6.6) 23 15.7 (7.3) 11 14.5 (6.2) 12
  Activated Positive Affect (APA) 10–50 11–47 28.1 (10.1) 23 31.2 (9.8) 11 25.5 (10.0) 12
  Unactivated Positive Affect (UPA) 3–15 3–14 9.1 (3.1) 23 8.7 (2.6) 11 9.4 (3.5) 12
Day 14
  Negative Affect (NA) 10–50 10–32 14.1 (5.7) 22 13.4 (3.7) 11 14.8 (7.3) 11
  Activated Positive Affect (APA) 10–50 10–41 24.6 (11.5) 22 26.3 (11.2) 11 23.0 (12.1) 11
  Unactivated Positive Affect (UPA) 3–15 3–15 8.2 (3.7) 22 8.5 (3.4) 11 7.9 (4.1) 11
8 Week Follow-Up
  Negative Affect (NA) 10–50 10–33 17.3 (6.4) 22 15.1 (4.6) 11 19.5 (7.3) 11
  Activated Positive Affect (APA) 10–50 15–45 32.4 (10.4) 22 35.2 (9.4) 11 29.5 (10.9) 11
  Unactivated Positive Affect (UPA) 3–15 4–13 9.1 (3.0) 22 9.4 (3.0) 11 8.8 (3.1) 11
Grateful Disposition
Baseline 6–42 15–42 35.8 (7.2) 23 36.9 (6.7) 11 34.8 (7.8) 12
Day 7 6–42 17–42 36.1 (7.0) 22 37.0 (7.0) 11 35.2 (7.2) 11
Day 14 6–42 13–42 36.3 (7.6) 22 37.3 (7.1) 11 35.4 (8.4) 11
8 Week Follow-Up 6–42 14–42 36.8 (7.2) 22 38.4 (6.2) 11 35.2 (8.0) 11
Number of Participants who Drank During Study Period* 3 (13.6%) 22 2 (18.2%) 11 1 (9.1%) 11
*

Determined at the 8 Week Follow Up, assessed with an electronic version of the Time Line Follow-Back (Pedersen, Grow, Duncan, Neighbors, & Larimer, 2012; Sobell & Sobell, 1992) and with the following individual items: ‘What, if any, was the date of your last drink?’ ‘What, if any, was the date of your last drug use?’

**

Assessed via the Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)

***

Assessed by the Obsessive-Compulsive Drinking Scale (OCDS) (Anton, Moak, & Latham, 1995)

****

Assessed by the Short Index of Problems (SIP) (Miller, Tonigan, & Longabaugh, 1995)

*****

Assessed via the Alcoholics Anonymous Affiliation Scale (Humphreys, Kaskutas, & Weisner, 1998)

Differences between the treatment and placebo groups were tested for all values reported in this table using t tests, chi square analyses, or Fisher’s Exact tests. No differences between groups were statistically significant.